Palbociclib plus endocrine therapy compared to ET alone for HR+/HER2- metastatic breast cancer
Dr. Khandan Keyomarsi
Cyclin-dependent-kinase-4/6 inhibitor (CDKi) plus endocrine therapy (ET) is standard of care for patients with advanced HR-positive, HER2-negative breast cancer. Retrospective analysis of the Breast Medical Oncology database at MD Anderson Cancer Center (Houston, TX) found that palbociclib in combination with ET, compared to ET alone, was associated with improved progression-free survival in both first- and second-line settings, and with improved overall survival in the second-line setting.
